Newsletter Signup | Join Community
Early phase trial suggests PARP inhibitor combination show promise in treating hard to treat patients with SCLC
Liquid biopsies improves access to treatment options for lung and MSI-High colon, GI, and uterine cancers.
Study suggest immune checkpoint inhibitor therapy effective treatment for earlier stage NSCLC.
Imfinzi immunotherapy becomes standard treatment for stage III NSCLC - decreases progression and prolongs survival.
The BiTE antibody construct may represent the next advance in the treatment of EGFR + NSCLC.
Chemotherapy, biomarker testing and precision cancer medicines and immunotherapy are part of recurrent NSCLC treatment.
Local ablative treatment combined with immunotherapy improves long term survival in oligometastatic NSCLC.
Avastin can be effectively combined with chemotherapy, immunotherapy, and tyrosine kinase inhibitors to treat NSCLC.
Chemotherapy, biomarker testing and precision cancer medicines and immunotherapy are used to treat stage IIIB-IV NSCLC.
Patients With NSCLC Are Not Undergoing Biomarker Testing for Precision Medicines-Patient Education is Key
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…